Serotype VI group B *Streptococcus* (GBS), which is common in Japan (prevalence rates 16%--40%) and has recently emerged in Malaysia and Taiwan, remains rare in Europe and North America ([@R1]--[@R4]). However, invasive serotype VI infections have been noticed in Alberta and Ontario, Canada ([@R5],[@R6]), and unpublished surveillance data for Canada (National Microbiology Laboratory, <https://www.canada.ca/en/public-health/services/publications/drugs-health-products/national-laboratory-surveillance-invasive-streptococcal-disease-canada-annual-summary-2015.html>) show low frequency (1.2%--4.1%) but sustained isolation of this GBS serotype in recent years. Here, we characterize a collection of 26 invasive serotype VI GBS strains recovered by passive surveillance in central Canada during 2010--2014 ([Technical Appendix 1](#SD1){ref-type="local-data"}). Two isolates came from early onset disease (patients age 0--6 days) and 1 from late-onset disease (patients age 7--90 days). Twenty-two isolates came from adult patients (9 age 18--60 years and 13 age \>60 years, a distribution similar to that reported for adult patients with serotype V or serotype IV invasive disease in Canada \[[@R5],[@R6]\]). Patient age was not available for 1 isolate.

We sequenced the genomes of all isolates using Illumina technology (Illumina, San Diego, CA, USA; National Center for Biotechnology Information BioProject PRJNA420560) and performed in silico multilocus sequence typing. Isolates belonged to sequence types (STs) ST889 (n = 1), ST297 (n = 1), ST14 (n = 2), and ST1 (n = 22) ([Technical Appendix 1](#SD1){ref-type="local-data"}). ST297, ST14, and ST1 are members of clonal complex (CC) 1; most serotype IV and V isolates responsible for adult disease in Canada also belong to CC1 ([@R5]--[@R7]). However, genome-wide, single-nucleotide polymorphism (SNP)--based phylogenetic analysis showed that CC1 isolates of these 3 serotypes are genetically dissimilar ([Technical Appendix 2](#SD1){ref-type="local-data"} Figure 1; genome-wide SNPs were identified relative to the genome of GBS-M002, a serotype VI isolate from Taiwan \[GenBank accession no. CP013908.1\]). Antimicrobial drug resistance among serotype VI isolates was, overall, similar to that described among serotype IV and V isolates causing adult invasive disease in Canada ([@R5],[@R8]) (MICs for penicillin, erythromycin, clindamycin, tetracycline, and vancomycin were determined using the agar dilution method or Etest according to Clinical and Laboratory Standards Institute guidelines \[[@R9]\]). All serotype VI isolates were susceptible to penicillin and vancomycin ([Technical Appendix 1](#SD1){ref-type="local-data"}). Resistance to erythromycin was found in 10 (38%) invasive isolates, resistance to clindamycin in 9 (35%), and resistance to tetracycline in 8 (31%) ([Technical Appendix 1](#SD1){ref-type="local-data"}). All lincosamide- and macrolide-resistant strains possessed gene *ermB*; 1 isolate had genes *mefA* and *msrD*. Genes *tetS*, *tetM*, and *tetO* were associated with observed resistance to tetracycline ([Technical Appendix 1](#SD1){ref-type="local-data"}).

Most (n = 22) ST1 isolates in our collection had a pilus island (PI) profile consisting of PI-1 containing the recently described PI-1 backbone protein subunit BP-1b ([@R10]) (BP1b-PI-1), in combination with PI-2a ([Technical Appendix 1](#SD1){ref-type="local-data"}). One ST1 isolate (NGBS1605) possessed the traditional PI-1 and PI-2a ([Technical Appendix 1](#SD1){ref-type="local-data"}). The ST14 isolates had BP1b-PI-1 and PI-2b. The ST889 isolate possessed only PI-2a ([Technical Appendix 1](#SD1){ref-type="local-data"}). We found differences among isolates in genes encoding α-like proteins (Alps): the ST297 isolate and most ST1 strains had gene *bca* encoding α-C protein. ST1 isolates NGBS543 and NGBS1605 possessed gene *alp3*, encoding Alp3. The ST14 and ST889 isolates possessed gene *alp1*, encoding Alp1 (or epsilon) protein ([Technical Appendix 1](#SD1){ref-type="local-data"}).

We next examined the extent of genetic diversity among the numerically dominant group of serotype VI ST1 organisms. For comparative purposes, genome data for 3 additional serotype VI strains were included (French strain CCH330, SRA accession no. ERX298473; Malaysian strain PR06, GenBank accession no. AOSD00000000.1; and 1 temporally matched serotype VI isolate recovered from a colonized pregnant woman in Canada; [Technical Appendix 1](#SD1){ref-type="local-data"}). Recombination was the main driver of genetic diversity among serotype VI ST1 organisms. Most (n = 16) ST1 isolates clustered closely with Malaysia strain PR06 ([Technical Appendix 2](#SD1){ref-type="local-data"} Figure 2). This clade (arbitrarily named the Malaysian clade) included most ST1 isolates with resistance to erythromycin and clindamycin. Recombination in a region of ≈200 kbp containing the genes encoding the 2-component virulence regulator CsrRS differentiated the Malaysian clade from a second clade formed by 5 Canadian isolates and the French and Taiwanese ST1 isolates (arbitrarily named the Taiwanese clade) ([Technical Appendix 2](#SD1){ref-type="local-data"} Figure 2). Recombination also explains the aforementioned differences in Alp- and pilus subunit--encoding genes among serotype VI ST1 strains. Isolates NGBS543 and NGBS1605 differed from other ST1 isolates by recombination in a region spanning 107 and 89 kbp, respectively, containing Alp-encoding genes. These 2 isolates also differed between themselves by recombination in the PI-1 locus ([Technical Appendix 2](#SD1){ref-type="local-data"} Figure 2).

Global travel and migration are known contributors to the emergence of bacterial clones in new geographies ([@R11]). Serotype VI GBS infections have emerged in Malaysia and Taiwan ([@R3],[@R4]). The population of serotype VI GBS isolates in Canada is dominated by 2 ST1 clades, each closely related genetically to the Malaysian or Taiwanese isolates. Although it is tempting to speculate that these 2 ST1 genotypes were introduced into Canada from overseas, the speculation cannot be fully supported by our current limited dataset. Continued monitoring for serotype VI GBS infections is warranted.
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**Technical Appendix 1.** Characteristics of serotype VI group B *Streptoccoccus* isolates used in this study.
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**Technical Appendix 2.** Figures describing phylogenetic relationships among serotype VI group B *Streptococcus* strains.
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